Search Results

1 - 10 of 181 items :

Clear All

REFERENCES 1. Abdel-Magid A. F. (2015). Inhibitors of the Antiapoptotic Myeloid Cell Leukemia-1 (Mcl-1) May Provide Effective Treatment for Cancer. ACS Medical Chemistry Letter, 6: 1171–1173. dx.doi.org/10.1021/acsmedchemlett.5b00438 2. AlBakr R. B, Khojah O. T. (2014). Incidence Trend of the Leukemia Reported Cases in the Kingdom of Saudi Arabia, Observational Descriptive Statistic from Saudi Cancer Registry. International Journal Biomedical Research, 5(8). 3. Anderson M. A, Huang D, Robertsa A. 2014. Targeting BCL2 for the Treatment of Lymphoid Malignancies

ABBREVIATIONS Bcl2 - B-cell lymphoma 2 CLL - Chronic lymphocytic leukaemia mRNA – messenger ribonucleic acid miRNA - micro ribonucleic acid qRT-PCR - quantitative reverse-transcriptase polymerase chain reaction REFERENCES 1. Sagatys EM, Zhang L. Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. Cancer Control 2012;19(1):18-25. 2. Chiorazzi N. Implications of new prognostic markers in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012;2012:76-87. 3. Obermann EC, Went P, Tzankov A, et al. Cell cycle phase

References Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009; 361(16): 1570-83. Jin Z, El-Deiry WS. Overview of cell death signalling pathways. Cancer Biol Ther 2005; 4(2): 139-163. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003; 22(53): 8543-67. Youle RJ, Strasser A. The BCL-2 family proteins: opposite activities that mediate cell death. Nat. Rev. Mol. Cell Biol 2008; 9(1): 47-59. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228(4706): 1440

unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011,44:517-531. 14. Dettwiler M, Croci M, Vaughan L, Guscetti F: Immunohistochemical expression study of proapoptotic BH3-only protein bad in canine nonneoplastic tissues and canine lymphomas. Vet Pathol 2013,50:789-796. 15. Jung JT, Kim DH, Kwak EK, Kim JG, Park TI, Sohn SK, Do YR, Kwon KY, Song HS, Park EH, Lee KB: Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas. Ann Hematol 2006,85:575-581. 16. Koshino A, Goto-Koshino Y, Setoguchi A, Ohno K

Genet. 1995; 11:101-5. 10.1016/S0168-9525(00)89010-1 5. Hall PA, Meek D, Lane DP. p53-integrating the complexity. J Pathol. 1996; 180:1-5. 10.1002/(SICI)1096-9896(199609)180:1<1::AID-PATH712>3.0.CO;2-U 6. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994; 9:1799-805. 7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993; 366:704-7. 8. Mork J, Lie AK

. Molecular mechanisms of myelodysplastic syndrome. Jpn J Clin Oncol. 2003;33(4):153-60. doi:10.1093/jjco/hyg037 PMID:12810828 Davis RE, Greenberg PL. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leuk Res. 1998;22(9):767-77. doi:10.1016/S0145-2126(98)00051-4 PMID:9716007

endocrine system. World Health Organization Classification of Tumors, IARC, Lyon: IARC Press. 2001; 86-91. 7. Cobanoglu B, Ozercan M.R. Staining characteristics of BCL-2, BAX, p53, p21, Ki-67 andC-erbB2 in thyroid carcinomas. Erciyes Medical Journal 2007; 29 (3): 201-209. 8. Viale G, Roncalli M, Grimelius L, Graziani D, Wilander E, Johansson H, et al.: Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum Pathol. 1995; 26(9): 945-50. 9. Gerasimovski D. Census of population, households and dwellings in the Republic of Macedonia, 2002 Final data

and -7 activity was analysed using the Muse Caspase-3/7 Assay Kit (Millipore Sigma, St Louis, MO, USA) according to the user’s guide. Assay results were measured using the Muse Cell Analyzer (Millipore Sigma). Determination of BAX and BCL2 gene expression RNA isolation and cDNA synthesis . The D-17 OSA cells into which nanoclinoptilolite was introduced were obtained in the form of pellets. For this purpose, cells were removed with trypsin-EDTA at the end of the incubation period and centrifugation was performed. RNA was isolated from the obtained cells using a

Wstęp W patogenezie wielu nowotworów, w tym nowotworów hematologicznych istotną rolę odgrywa zahamowanie apoptozy, w wyniku której dochodzi do akumulacji komórek patologicznych we krwi, szpiku kostnym, węzłach chłonnych lub narządach pozawęzłowych. Kluczowymi regulatorami wewnątrzpochodnego szlaku apoptozy są białka rodziny BCL-2 [ 1 ]. Nadekspresja promujących przeżycie, antyapoptotycznych białek BCL-2, przy jednocześnie zmniejszonej ekspresji białek proapoptotycznych jest charakterystyczna dla wielu chłoniaków B-komórkowych, w tym także dla przewlekłej

2000;60:4016-20. 54. Rodriguez-Villanueva J, Colome MI, Brisbay S, McDonnell TJ. The expression and localization of bcl-2 protein in normal skin and in non-melanoma skin cancers. Pathol Res Pract 1995;191:391-8. 55. Verhaegh ME, Sanders CJ, Arends JW, Neumann HA. Expression of the apoptosis-suppressing protein Bcl-2 in nonmelanoma skin cancer. Br J Dermatol 1995; 132: 740-4. 56. Poniecka AW, Alexis JB. An immunohistochemical study of basal cell carcinoma and trichoepithelioma. Am J Dermatopathol 1999;21:332-6. 57. Rossen K, Karabulut Thorup A, Hou-Jensen K, Krag